Accessibility Menu
Lexicon Pharmaceuticals logo

Lexicon Pharmaceuticals

(NASDAQ) LXRX

Current Price$2.54
Market Cap$1.02B
Since IPO (2000)-98%
5 Year-55%
1 Year+174%
1 Month+18%

Lexicon Pharmaceuticals Financials at a Glance

Market Cap

$1.02B

Revenue (TTM)

$69.64M

Net Income (TTM)

-$26.09M

EPS (TTM)

-$0.07

P/E Ratio

-32.03

Dividend

$0.00

Beta (Volatility)

1.60 (High)

Price

$2.54

Volume

409,053

Open

$2.28

Previous Close

$2.54

Daily Range

$2.28 - $2.55

52-Week Range

$0.80 - $2.55

Estimated Earnings Date

Aug 5, 2026

LXRX: Motley Fool Moneyball Superscore

56

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Lexicon Pharmaceuticals

Industry

Pharmaceuticals

Employees

81

CEO

Michael Exton, PhD

Headquarters

The Woodlands, TX 77381, US

LXRX Financials

Key Financial Metrics (TTM)

Gross Margin

99.07%

Operating Margin

-34.79%

Net Income Margin

-37.46%

Return on Equity

-18.64%

Return on Capital

-28.81%

Return on Assets

-9.71%

Earnings Yield

-3.12%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.02B

Shares Outstanding

444.20M

Volume

409.05K

Avg. Volume

2.49M

Financials (TTM)

Gross Profit

$69.00M

Operating Income

-$24.23M

EBITDA

-$17.44M

Operating Cash Flow

-$38.80M

Capital Expenditure

$0.00

Free Cash Flow

-$38.80M

Cash & ST Invst.

$170.66M

Total Debt

$57.71M

Lexicon Pharmaceuticals Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$21.10M

+1572.1%

Gross Profit

$20.99M

+1604.1%

Gross Margin

99.49%

N/A

Market Cap

$1.02B

N/A

Market Cap/Employee

$9.88M

N/A

Employees

103

N/A

Net Income

-$1.04M

+95.9%

EBITDA

$657.00K

+102.8%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$170.66M

-12.4%

Total Debt

$57.71M

-45.7%

Accounts Receivable

$11.78M

-75.2%

Inventory

$276.00K

+37.3%

Long Term Debt

$56.07M

-11.2%

Short Term Debt

$1.64M

-96.2%

Return on Assets

-9.71%

N/A

Return on Invested Capital

-9.36%

N/A

Free Cash Flow

-$14.73M

+66.4%

Operating Cash Flow

-$14.73M

+66.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
RAPTRAPT Therapeutics, Inc.
$58.01+0.00%
OMEROmeros Corporation
$8.67-19.12%
FDMT4D Molecular Therapeutics, Inc.
$11.60+0.69%
OCGNOcugen, Inc.
$1.50+9.49%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$7.83+0.02%
KEELKeel Infrastructure
$6.03+0.03%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.67+0.04%
NWLNewell Brands
$5.82-0.01%

Questions About LXRX

What is the current price of Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals is trading at $2.54 per share.

What is the 52-week range for Lexicon Pharmaceuticals?

Over the past 52 weeks, Lexicon Pharmaceuticals has traded between $0.80 and $2.55.

How much debt does Lexicon Pharmaceuticals have?

As of the most recent reporting period, Lexicon Pharmaceuticals reported total debt of $57.71M.

How much cash does Lexicon Pharmaceuticals have on hand?

Lexicon Pharmaceuticals reported $38.09M in cash and cash equivalents in its most recent financial results.

What is Lexicon Pharmaceuticals’s dividend yield?

Lexicon Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.